A French team has just provided proof that a drug already used to treat type 2 diabetes, lixisenatide, helps slow the progression of Parkinson's disease. The results of this new study - just published in the prestigious scientific journal New England Journal of Medicine - are presented as a world first.
“ These results are very positive, because we have been looking for molecules that could have this type of neuroprotective effect for decades, ” rejoice Professor Olivier Rascol, neuropharmacologist at Toulouse University Hospital.